SITC 2021 | Adverse events in the Phase II trial of AV-GBM-1

Daniela Bota, MD, PhD, The University of California, Irvine, Irvine, CA, discusses the adverse events that patients experienced in the Phase II trial of AV-GBM-1, a dendritic cell vaccine. The most notable adverse event was a slightly increased risk of seizures, which will need to be investigated in further trials. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.